AMN107

Tightening the grip of imatinib

Thomas O'Hare, Denise K. Walters, Michael W N Deininger, Brian Druker

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

The Abl inhibitor imatinib is a highly effective therapy for patients with chronic myeloid leukemia. Relapses are relatively uncommon in newly diagnosed patients, but are the rule in patients with more advanced disease. Mutations in the BCR-ABL gene are the most common cause of relapse. Working from the imatinib chemical structure, a higher-affinity family member, AMN107, was designed. AMN107 is approximately 20-fold more potent than imatinib, and this translates into improved inhibitory activity against most of the common BCR-ABL mutations. The implications of these results, and the potential role this and other novel ABL inhibitors may have in treating patients with CML, are discussed.

Original languageEnglish (US)
Pages (from-to)117-119
Number of pages3
JournalCancer Cell
Volume7
Issue number2
DOIs
StatePublished - Feb 2005

Fingerprint

Hand Strength
Recurrence
Mutation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Imatinib Mesylate
Genes
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Oncology

Cite this

O'Hare, T., Walters, D. K., Deininger, M. W. N., & Druker, B. (2005). AMN107: Tightening the grip of imatinib. Cancer Cell, 7(2), 117-119. https://doi.org/10.1016/j.ccr.2005.01.020

AMN107 : Tightening the grip of imatinib. / O'Hare, Thomas; Walters, Denise K.; Deininger, Michael W N; Druker, Brian.

In: Cancer Cell, Vol. 7, No. 2, 02.2005, p. 117-119.

Research output: Contribution to journalArticle

O'Hare, T, Walters, DK, Deininger, MWN & Druker, B 2005, 'AMN107: Tightening the grip of imatinib', Cancer Cell, vol. 7, no. 2, pp. 117-119. https://doi.org/10.1016/j.ccr.2005.01.020
O'Hare, Thomas ; Walters, Denise K. ; Deininger, Michael W N ; Druker, Brian. / AMN107 : Tightening the grip of imatinib. In: Cancer Cell. 2005 ; Vol. 7, No. 2. pp. 117-119.
@article{1f0308132857449fb989f158c8dc3bc5,
title = "AMN107: Tightening the grip of imatinib",
abstract = "The Abl inhibitor imatinib is a highly effective therapy for patients with chronic myeloid leukemia. Relapses are relatively uncommon in newly diagnosed patients, but are the rule in patients with more advanced disease. Mutations in the BCR-ABL gene are the most common cause of relapse. Working from the imatinib chemical structure, a higher-affinity family member, AMN107, was designed. AMN107 is approximately 20-fold more potent than imatinib, and this translates into improved inhibitory activity against most of the common BCR-ABL mutations. The implications of these results, and the potential role this and other novel ABL inhibitors may have in treating patients with CML, are discussed.",
author = "Thomas O'Hare and Walters, {Denise K.} and Deininger, {Michael W N} and Brian Druker",
year = "2005",
month = "2",
doi = "10.1016/j.ccr.2005.01.020",
language = "English (US)",
volume = "7",
pages = "117--119",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "2",

}

TY - JOUR

T1 - AMN107

T2 - Tightening the grip of imatinib

AU - O'Hare, Thomas

AU - Walters, Denise K.

AU - Deininger, Michael W N

AU - Druker, Brian

PY - 2005/2

Y1 - 2005/2

N2 - The Abl inhibitor imatinib is a highly effective therapy for patients with chronic myeloid leukemia. Relapses are relatively uncommon in newly diagnosed patients, but are the rule in patients with more advanced disease. Mutations in the BCR-ABL gene are the most common cause of relapse. Working from the imatinib chemical structure, a higher-affinity family member, AMN107, was designed. AMN107 is approximately 20-fold more potent than imatinib, and this translates into improved inhibitory activity against most of the common BCR-ABL mutations. The implications of these results, and the potential role this and other novel ABL inhibitors may have in treating patients with CML, are discussed.

AB - The Abl inhibitor imatinib is a highly effective therapy for patients with chronic myeloid leukemia. Relapses are relatively uncommon in newly diagnosed patients, but are the rule in patients with more advanced disease. Mutations in the BCR-ABL gene are the most common cause of relapse. Working from the imatinib chemical structure, a higher-affinity family member, AMN107, was designed. AMN107 is approximately 20-fold more potent than imatinib, and this translates into improved inhibitory activity against most of the common BCR-ABL mutations. The implications of these results, and the potential role this and other novel ABL inhibitors may have in treating patients with CML, are discussed.

UR - http://www.scopus.com/inward/record.url?scp=13844251983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13844251983&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2005.01.020

DO - 10.1016/j.ccr.2005.01.020

M3 - Article

VL - 7

SP - 117

EP - 119

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 2

ER -